CureVac (NASDAQ:CVAC) Sets New 52-Week Low at $9.35

CureVac (NASDAQ:CVACGet Rating) shares reached a new 52-week low during trading on Monday . The company traded as low as $9.35 and last traded at $9.47, with a volume of 107 shares. The stock had previously closed at $9.57.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reissued a “buy” rating and issued a $37.00 target price on shares of CureVac in a research report on Thursday, June 9th.

CureVac Stock Performance

The business’s fifty day moving average price is $11.86 and its 200 day moving average price is $15.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.45 and a quick ratio of 3.39.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Vontobel Holding Ltd. boosted its stake in shares of CureVac by 3.8% during the first quarter. Vontobel Holding Ltd. now owns 19,411 shares of the company’s stock worth $381,000 after buying an additional 702 shares during the period. Quadrant Capital Group LLC lifted its position in CureVac by 28.6% during the 2nd quarter. Quadrant Capital Group LLC now owns 3,769 shares of the company’s stock worth $51,000 after acquiring an additional 838 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of CureVac by 12.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,888 shares of the company’s stock valued at $155,000 after purchasing an additional 886 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of CureVac by 3.0% in the fourth quarter. Rhumbline Advisers now owns 47,769 shares of the company’s stock valued at $1,639,000 after purchasing an additional 1,403 shares during the period. Finally, Signaturefd LLC raised its stake in shares of CureVac by 226.3% during the first quarter. Signaturefd LLC now owns 2,392 shares of the company’s stock worth $47,000 after purchasing an additional 1,659 shares during the last quarter.

About CureVac

(Get Rating)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.

Further Reading

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.